Data from Eloxx’s proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback